Advertisement
HCAT vs PHR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCAT is a Hold and PHR is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HCAT’s FA Score shows that 1 FA rating(s) are green whilePHR’s FA Score has 0 green FA rating(s).
- HCAT’s FA Score: 1 green, 4 red.
- PHR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HCAT’s TA Score shows that 4 TA indicator(s) are bullish while PHR’s TA Score has 5 bullish TA indicator(s).
- HCAT’s TA Score: 4 bullish, 6 bearish.
- PHR’s TA Score: 5 bullish, 3 bearish.
Price Growth
HCAT (@Services to the Health Industry) experienced а +11.11% price change this week, while PHR (@Services to the Health Industry) price change was +7.26% for the same time period.
The average weekly price growth across all stocks in the @Services to the Health Industry industry was +3.52%. For the same industry, the average monthly price growth was +3.82%, and the average quarterly price growth was +6.78%.
Reported Earning Dates
HCAT is expected to report earnings on Nov 11, 2025.
PHR is expected to report earnings on Sep 03, 2025.
Industries' Descriptions
@Services to the Health Industry (+3.52% weekly)This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.
| HCAT | PHR | HCAT / PHR | |
| Capitalization | 211M | 1.73B | 12% |
| EBITDA | -27.89M | -9.46M | 295% |
| Gain YTD | -57.567 | 15.660 | -368% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 316M | 435M | 73% |
| Total Cash | 97.3M | 90.9M | 107% |
| Total Debt | 173M | 15.9M | 1,088% |
HCAT | PHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | 44 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 98 | |
SMR RATING 1..100 | 96 | 95 | |
PRICE GROWTH RATING 1..100 | 93 | 49 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HCAT's Valuation (27) in the null industry is in the same range as PHR (44). This means that HCAT’s stock grew similarly to PHR’s over the last 12 months.
PHR's Profit vs Risk Rating (98) in the null industry is in the same range as HCAT (100). This means that PHR’s stock grew similarly to HCAT’s over the last 12 months.
PHR's SMR Rating (95) in the null industry is in the same range as HCAT (96). This means that PHR’s stock grew similarly to HCAT’s over the last 12 months.
PHR's Price Growth Rating (49) in the null industry is somewhat better than the same rating for HCAT (93). This means that PHR’s stock grew somewhat faster than HCAT’s over the last 12 months.
PHR's P/E Growth Rating (100) in the null industry is in the same range as HCAT (100). This means that PHR’s stock grew similarly to HCAT’s over the last 12 months.
| HCAT | PHR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | N/A |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 71% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 79% |
| Advances ODDS (%) | 6 days ago 72% | 1 day ago 81% |
| Declines ODDS (%) | 4 days ago 81% | 18 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 89% | N/A |
Advertisement